Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Timothy Devos, Dominik Selleslag, Pierre Zachée & Fleur Samantha Benghiat. (2018) Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology 23:4, pages 194-200.
Read now
Read now
Articles from other publishers (3)
Francesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, Mario Tiribelli, Giulia Benevolo, Bruno Martino, Elisabetta Abruzzese, Mariella D’Adda, Nicola Polverelli, Micaela Bergamaschi, Alessia Tieghi, Francesco Cavazzini, Adalberto Ibatici, Monica Crugnola, Costanza Bosi, Roberto Latagliata, Ambra Di Veroli, Luigi Scaffidi, Federico de Marchi, Elisa Cerqui, Barbara Anaclerico, Giovanna De Matteis, Marco Spinsanti, Elena Sabattini, Lucia Catani, Franco Aversa, Francesco Di Raimondo, Umberto Vitolo, Roberto Massimo Lemoli, Renato Fanin, Francesco Merli, Domenico Russo, Antonio Cuneo, Maria Letizia Bacchi Reggiani, Michele Cavo, Nicola Vianelli & Massimo Breccia. (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8:45, pages 79073-79086.
Crossref
Crossref
K. Gowin, H. Kosiorek, A. Dueck, J. Mascarenhas, R. Hoffman, C. Reeder, J. Camoriano, R. Tibes, K. Gano, J. Palmer & R. Mesa. (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia Research 60, pages 31-35.
Crossref
Crossref
Arturo J Martí-Carvajal, Vidhu Anand & Ivan Solà. (2015) Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref